The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease

Immunology

Volumn 125, Issue 2, 2008, Pages 145-153

  Himmel, Megan E ^a,b   Hardenberg, Gijs ^a,b   Piccirillo, Ciriaco A ^c   Steiner, Theodore S ^b   Levings, Megan K ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Flagellin; Human; Inflammatory bowel disease; T regulatory cell; Toll like receptor

Indexed keywords

BACTERIAL ANTIGEN; FLAGELLIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3;

ADAPTIVE IMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE FUNCTION TEST; IMMUNOREGULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS;

ANIMALS; ANTIGENS, BACTERIAL; FLAGELLIN; HUMANS; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE COUNT; MICE; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTORS;

EID: 51249111466     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.02939.x     Document Type: Review

References (95)

1. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007 117:514 21.
2. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008 8:458 66.
3. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004 126:1504 17.
4. Izcue A, Powrie F. Special regulatory T-cell review: regulatory T cells and the intestinal tract - patrolling the frontier. Immunology 2008 123:6 10.
5. + T cells during cure of colitis. J Immunol 2006 177:5852 60.
6. Vieira P, O'Garra A. Regula'ten' the gut. Nat Immunol 2007 8:905 7.
7. + T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993 5:1461 71.
8. Strauch UG, Obermeier F, Grunwald N et al. Influence of intestinal bacteria on induction of regulatory T cells: lessons from a transfer model of colitis. Gut 2005 54:1546 52.
9. +, CD45RBhigh T cells to SCID recipients. J Immunol 1997 158:3464 73.
10. + regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J Immunol 2003 171:5012 7.
11. + T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 2003 197:111 9.
12. Takahashi M, Nakamura K, Honda K et al. An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Dig Dis Sci 2006 51:677 86.
13. + CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005 128:1868 78.
14. + regulatory T cells in Crohn's disease. Clin Immunol 2007 125:281 90.
15. + CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004 173:3119 30.
16. + regulatory T cells in ulcerative colitis. Inflamm Bowel Dis 2007 13:191 9.
17. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004 200:277 85.
18. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005 54:92 9.
19. Muratov V, Ulfgren AK, Engstrom M, Elvin K, Winqvist O, Lofberg R, Lundahl J. Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis. J Gastroenterol 2008 43:277 82.
20. + CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis 2006 12:447 56.
21. + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004 199:971 9.
22. Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J Immunol 2002 169:6210 7.
23. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007 19:345 54.
24. + T cells. Eur J Immunol 2007 37:129 38.
25. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007 123:18 29.
26. Gavin MA, Torgerson TR, Houston E et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006 103:6659 64.
27. + FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007 110:2983 90.
28. + T cells. Int Immunol 2008 20:1041 55.
29. + regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J Immunol 2008 180:7112 6.
30. - T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol 2007 178:6725 9.
31. Pasare C, Medzhitov R. Toll-like receptors: balancing host resistance with immune tolerance. Curr Opin Immunol 2003 15:677 82.
32. Kabelitz D. Expression and function of toll-like receptors in T lymphocytes. Curr Opin Immunol 2007 19:39 45.
33. Sutmuller R, Garritsen A, Adema GJ. Regulatory T cells and toll-like receptors: regulating the regulators. Ann Rheum Dis 2007 66 (Suppl. 3 iii91 5.
34. Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 2008 27:168 80.
35. Weber CR, Turner JR. Inflammatory bowel disease: is it really just another break in the wall? Gut 2007 56:6 8.
36. + T cell effector function in a murine model of inflammatory bowel disease. J Immunol 2008 180:1886 94.
37. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci USA 2004 101:3029 34.
38. Imanishi T, Hara H, Suzuki S, Suzuki N, Akira S, Saito T. Cutting edge: TLR2 directly triggers Th1 effector functions. J Immunol 2007 178:6715 9.
39. + T cells. J Immunol 2005 175:1551 7.
40. + T cell survival. J Immunol 2004 172:6065 73.
41. Hayashi F, Smith KD, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature 2001 410:1099 103.
42. Steiner TS. How flagellin and toll-like receptor 5 contribute to enteric infection. Infect Immun 2007 75:545 52.
43. + T regulatory cells. J Immunol 2005 175:8051 9.
44. Ye Z, Lee CM, Sun GW, Gan YH. Burkholderia pseudomallei infection of T cells leads to T-cell costimulation partially provided by flagellin. Infect Immun 2008 76:2541 50.
45. + T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity 2006 25:783 93.
46. van Maren WW, Jacobs JF, de Vries IJ, Nierkens S, Adema GJ. Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology 2008 124:445 52.
47. Sutmuller RP, den Brok MH, Kramer M et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006 116:485 94.
48. + regulatory T cells. Proc Natl Acad Sci USA 2006 103:7048 53.
49. + regulatory T cell function via innate TLR2 signaling. J Clin Invest 2006 116:2022 32.
50. + regulatory T cell function. Science 2005 309:1380 4.
51. + T cells. Immunol Lett 2007 108:183 8.
52. Wu X, Peng SL. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum 2006 54:336 42.
53. Zanin-Zhorov A, Tal-Lapidot G, Cahalon L, Cohen-Sfady M, Pevsner-Fischer M, Lider O, Cohen IR. Cutting edge: T cells respond to lipopolysaccharide innately via TLR4 signaling. J Immunol 2007 179:41 4.
54. Raffeiner B, Dejaco C, Duftner C et al. Between adaptive and innate immunity: TLR4-mediated perforin production by CD28null T-helper cells in ankylosing spondylitis. Arthritis Res Ther 2005 7:R1412 20.
55. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003 197:403 11.
56. + T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J Immunol 2006 177:7155 63.
57. Cario E. Therapeutic impact of toll-like receptors on inflammatory bowel diseases: a multiple-edged sword. Inflamm Bowel Dis 2008 14:411 21.
58. + T cells in chronic colitis. J Immunol 2008 180:5291 9.
59. + T cells which prevent intestinal inflammation in the SCID transfer model of colitis. Gut 2005 54:1428 36.
60. Uematsu S, Jang MH, Chevrier N et al. Detection of pathogenic intestinal bacteria by toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol 2006 7:868 74.
61. Vijay-Kumar M, Sanders CJ, Taylor RT et al. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 2007 117:3909 21.
62. Gewirtz AT, Vijay-Kumar M, Brant SR, Duerr RH, Nicolae DL, Cho JH. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2006 290:G1157 63.
63. Hawn TR, Verbon A, Lettinga KD et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med 2003 198:1563 72.
64. Franchi L, Amer A, Body-Malapel M et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol 2006 7:576 82.
65. Uematsu S, Fujimoto K, Jang MH et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing toll-like receptor 5. Nat Immunol 2008 9:769 76.
66. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. The toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 2003 170:5165 75.
67. Maaser C, Heidemann J, von Eiff C et al. Human intestinal microvascular endothelial cells express toll-like receptor 5: a binding partner for bacterial flagellin. J Immunol 2004 172:5056 62.
68. De Jager PL, Franchimont D, Waliszewska A et al. The role of the toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun 2007 8:387 97.
69. Pierik M, Joossens S, Van Steen K, Van Schuerbeek N, Vlietinck R, Rutgeerts P, Vermeire S. Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis 2006 12:1 8.
70. Torok HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004 127:365 6.
71. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000 68:7010 7.
72. Szebeni B, Veres G, Dezsofi A, Rusai K, Vannay A, Mraz M, Majorova E, Arato A. Increased expression of toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol 2008 151:34 41.
73. Canto E, Ricart E, Monfort D, Gonzalez-Juan D, Balanzo J, Rodriguez-Sanchez JL, Vidal S. TNF alpha production to TLR2 ligands in active IBD patients. Clin Immunol 2006 119:156 65.
74. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005 206:260 76.
75. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002 20:495 549.
76. Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 2006 25:319 29.
77. Brandwein SL, McCabe RP, Cong Y et al. Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J Immunol 1997 159:44 52.
78. + T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998 187:855 64.
79. Elson CO, Cong Y, Sundberg J. The C3H/HeJBir mouse model: a high susceptibility phenotype for colitis. Int Rev Immunol 2000 19:63 75.
80. Brimnes J, Reimann J, Nissen M, Claesson M. Enteric bacterial antigens activate CD4(+) T cells from scid mice with inflammatory bowel disease. Eur J Immunol 2001 31:23 31.
81. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative Gastroenterology 1999 116:1246 9.
82. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995 102:448 55.
83. Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Buschenfelde KH. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut 1999 44:812 8.
84. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004 113:1296 306.
85. Gewirtz AT. TLRs in the Gut. III. Immune responses to flagellin in Crohn's disease: good, bad, or irrelevant Am J Physiol Gastrointest Liver Physiol 2007 292:G706 10.
86. Sanders CJ, Yu Y, Moore DA 3rd., Williams IR, Gewirtz AT. Humoral immune response to flagellin requires T cells and activation of innate immunity. J Immunol 2006 177:2810 8.
87. Duck LW, Walter MR, Novak J, Kelly D, Tomasi M, Cong Y, Elson CO. Isolation of flagellated bacteria implicated in Crohn's disease. Inflamm Bowel Dis 2007 13:1191 201.
88. Sitaraman SV, Klapproth JM, Moore DA 3rd., Landers C, Targan S, Williams IR, Gewirtz AT. Elevated flagellin-specific immunoglobulins in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2005 288:G403 6.
89. Targan SR, Landers CJ, Yang H et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005 128:2020 8.
90. Zarember KA, Godowski PJ. Tissue expression of human toll-like receptors and differential regulation of toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002 168:554 61.
91. Mansson A, Adner M, Cardell LO. Toll-like receptors in cellular subsets of human tonsil T cells: altered expression during recurrent tonsillitis. Respir Res 2006 7:36.
92. Sobek V, Birkner N, Falk I et al. Direct toll-like receptor 2 mediated co-stimulation of T cells in the mouse system as a basis for chronic inflammatory joint disease. Arthritis Res Ther 2004 6:R433 46.
93. Bell MP, Svingen PA, Rahman MK, Xiong Y, Faubion WA Jr. FOXP3 regulates TLR10 expression in human T regulatory cells. J Immunol 2007 179:1893 900.
94. + T cells. Immunology 2007 122:149 56.
95. Marsland BJ, Nembrini C, Grun K, Reissmann R, Kurrer M, Leipner C, Kopf M. TLR ligands act directly upon T cells to restore proliferation in the absence of protein kinase C-theta signaling and promote autoimmune myocarditis. J Immunol 2007 178:3466 73.